. . "Ronald Ogilvie, \"Process for the preparation of eletriptan.\" U.S. Patent US20050059828, issued March 17, 2005."@en . "Exposure to the product (area below curve) and maximum concentrations are increased when product is taken with a high-fat meal."@en . . "Eletriptan is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches. [Wikipedia]"@en . " "@en . "Eletriptanum"@en . . "* Renal cl=3.9 L/h"@en . . . . . . . . "Eletriptan binds with high affinity to 5-HT1B, 5-HT1D and 5-HT1F receptors, has modest affinity for 5-HT1A, 5-HT1E, 5-HT2B and 5-HT7 receptors, and little or no affinity for 5-HT2A, 5-HT2C, 5-HT3, 5-HT4, 5-HT5A and 5-HT6 receptors. Eletriptan has no significant affinity or pharmacological activity at adrenergic alpha1, alpha2, or beta; dopaminergic D1 or D2; muscarinic; or opioid receptors. Two theories have been proposed to explain the efficacy of 5-HT receptor agonists in migraine. One theory suggests that activation of 5-HT1 receptors located on intracranial blood vessels, including those on the arteriovenous anastomoses, leads to vasoconstriction, which is correlated with the relief of migraine headache. The other hypothesis suggests that activation of 5-HT1 receptors on sensory nerve endings in the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release."@en . . . . . . . . . "* 138 L"@en . . . . . . . . . . . "Plasma protein binding is moderate and approximately 85%."@en . . . . . . "The terminal elimination half-life of eletriptan is approximately 4 hours."@en . . "Eletriptan"@en . . . . . . . . "For the acute treatment of migraine with or without aura in adults."@en . . . "Based on the pharmacology of the 5-HT1B/1D agonists, hypertension or other more serious cardiovascular symptoms could occur on overdose."@en . . "approved"@en . "Well absorbed after oral administration with a mean absolute bioavailability of approximately 50%."@en . . "143322-58-1"@en . . . "Humans and other mammals"@en . "investigational"@en . . . . . . . . . . . " "@en . . . . . . . .